Vaxart, Inc. (OTCQX: VXRT) creates clinical and stockholder committees
Rhea-AI Filing Summary
Vaxart, Inc. (VXRT) reports that its Board of Directors has created two new committees: a Clinical and Regulatory Affairs Committee and a Stockholder Engagement Committee. The new Clinical and Regulatory Affairs Committee will review and provide oversight and advice on Vaxart’s research, clinical, and regulatory programs on behalf of the Board, and consists of James B. Breitmeyer, M.D., Ph.D. (Chair) and David Wheadon, M.D.. The Stockholder Engagement Committee will oversee the advancement of the company’s relations with stockholders, and consists of W. Mark Watson (Interim Chair) and Steven Lo. Under a Cooperation Agreement dated July 1, 2026, Vaxart anticipates appointing a new director in the future to serve as Chair of the Stockholder Engagement Committee. Vaxart notes that its common stock is quoted on the OTCQX Best Market under the symbol VXRT and includes a standard forward-looking statements disclaimer regarding the anticipated new director appointment.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Board action date: August 21, 2026
Cooperation Agreement date: July 1, 2026
Trading symbol: VXRT
3 metrics
Board action date
August 21, 2026
Date the Board formed the two new committees
Cooperation Agreement date
July 1, 2026
Date of Cooperation Agreement referenced for future director appointment
Trading symbol
VXRT
Symbol for Vaxart’s common stock quoted on the OTCQX Best Market
Key Terms
Clinical and Regulatory Affairs Committee, Stockholder Engagement Committee, Cooperation Agreement, forward-looking statements
4 terms
Clinical and Regulatory Affairs Committee regulatory
"formed two new committees of the Board: the Clinical and Regulatory Affairs Committee"
A clinical and regulatory affairs committee is a group within a company that guides how medical studies are run and how products are brought into compliance with health authorities. Like a navigator and traffic controller for a drug or device, it sets strategy, reviews safety and study design, and helps manage approval pathways; its decisions influence development timelines, costs, and the likelihood a product reaches the market, which directly affects investor value.
Stockholder Engagement Committee financial
"formed two new committees of the Board: the Clinical and Regulatory Affairs Committee and the Stockholder Engagement Committee"
A stockholder engagement committee is a group, usually of board members, set up to communicate with shareholders, gather their views, and advise the board on investor concerns and priorities. It matters to investors because it creates a formal channel—like a dedicated liaison or customer service team—for raising governance, strategy or compensation questions, and can influence company decisions and transparency that affect share value and risk.
Cooperation Agreement regulatory
"Pursuant to that certain Cooperation Agreement, dated as of July 1, 2026"
A cooperation agreement is a formal contract between two or more organizations that lays out who will do what, how resources and responsibility are shared, how benefits or costs are divided, and how disputes or exits are handled. Like two chefs agreeing on a shared recipe and kitchen duties, it matters to investors because it can create new revenue paths, shift costs or risks, affect who controls key assets or technologies, and change a company’s future growth prospects.
forward-looking statements regulatory
"Cautionary Note Regarding Forward-Looking Statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What governance changes did Vaxart, Inc. (VXRT) announce on August 21, 2026?
Vaxart’s Board formed a Clinical and Regulatory Affairs Committee and a Stockholder Engagement Committee. These committees add Board-level oversight for research, clinical and regulatory programs, and for the company’s relations with stockholders, with specific directors appointed to each committee.
Who serves on Vaxart’s new Clinical and Regulatory Affairs Committee?
The Clinical and Regulatory Affairs Committee includes James B. Breitmeyer, M.D., Ph.D., who serves as Chair, and David Wheadon, M.D.. The committee is responsible for reviewing and providing oversight and advice on Vaxart’s research, clinical, and regulatory programs on behalf of the Board.
Who serves on Vaxart’s new Stockholder Engagement Committee and who is Interim Chair?
The Stockholder Engagement Committee includes W. Mark Watson and Steven Lo, with Mr. Watson serving as Interim Chair. The committee is responsible for overseeing the advancement of Vaxart’s relations with its stockholders.
What future Board change does Vaxart (VXRT) anticipate under its Cooperation Agreement?
Under a Cooperation Agreement dated July 1, 2026, Vaxart anticipates appointing a new director to its Board in the future who will serve as Chair of the Stockholder Engagement Committee. The company characterizes this appointment as a forward-looking expectation.
On which market is Vaxart (VXRT) currently quoted?
Vaxart states that its common stock is quoted on the OTCQX Best Market under the symbol “VXRT”. This disclosure appears in connection with its description of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
AI-generated analysis. How Rhea-AI works. Not financial advice.
